Exact Sciences Corporation (EXAS) Financial Statements

Financials
SegmentsShareholders

Exact Sciences financial statements at a glance

Exact Sciences reported revenue of $3.25 billion for fiscal year 2025 (ended December 31, 2025), up 17.7% from fiscal year 2024. Net income was -$207.95 million, a net margin of 6.4% loss, and diluted earnings per share were -$1.10.

At the end of fiscal year 2025 it had total assets of $5.86 billion, total liabilities of $3.46 billion and shareholders' equity of $2.40 billion, with cash and short-term investments of $964.71 million and total debt of $2.52 billion.

Its operations brought in $491.44 million of cash; capital spending was $134.66 million, leaving free cash flow of $356.78 million.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

EXAS logo

Exact Sciences Corporation

EXASUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
3.25B
Prev Year: 2.76B
YoY: +17.7%
Operating Revenue
3.25B
Prev Year: 2.76B
YoY: +17.7%
Total Unusual Items Excluding Goodwill
34.57M
Prev Year: -819.65M
YoY: +104.2%
Total Unusual Items
34.57M
Prev Year: -819.65M
YoY: +104.2%
Normalized EBITDA
17.87M
Prev Year: 30.32M
YoY: -41.1%
Tax Rate for Calcs
0.21
Prev Year: 0
Tax Effect of Unusual Items
7.26M
Prev Year: -4.92M
YoY: +247.6%
Impairment of Capital Assets
7.20M
Prev Year: 869.46M
YoY: -99.2%
Total Other Finance Cost
4.61M
Prev Year: 5.30M
YoY: -13.0%
Selling and Marketing Expense
1.05B
Prev Year: 247.50M
YoY: +324.3%
General and Administrative Expense
888.67M
Prev Year: 1.42B
YoY: -37.4%
Other General and Administrative
888.67M
Prev Year: 419.20M
YoY: +112.0%
Cost of Revenue
984.24M
Prev Year: 840.20M
YoY: +17.1%
Gross Profit
2.26B
Prev Year: 1.92B
YoY: +17.9%
Operating Expense
2.46B
Prev Year: 2.10B
YoY: +17.4%
Selling General and Administrative
1.94B
Prev Year: 1.67B
YoY: +16.2%
Research and Development
523.00M
Prev Year: 431.21M
YoY: +21.3%
Operating Income
-199.10M
Prev Year: -179.14M
YoY: -11.1%
Net Non Operating Interest Income Expense
-39.36M
Prev Year: -37.27M
YoY: -5.6%
Non-operating Interest Expense
34.75M
Prev Year: 31.97M
YoY: +8.7%
Non-operating Interest Income
-
Other Income Expense
34.57M
Prev Year: -819.65M
YoY: +104.2%
Gain on Sale of Securities
41.77M
Prev Year: 39.56M
YoY: +5.6%
Special Income Charges
-7.20M
Prev Year: -859.21M
YoY: +99.2%
Pre-tax Income
-203.89M
Prev Year: -1.04B
YoY: +80.3%
Provision for Income Taxes
4.06M
Prev Year: -7.30M
YoY: +155.6%
Net Income Common Stockholders
-207.95M
Prev Year: -1.03B
YoY: +79.8%
Net Income
-207.95M
Prev Year: -1.03B
YoY: +79.8%
Net Income Including Non-Controlling Interests
-207.95M
Prev Year: -1.03B
YoY: +79.8%
Net Income from Continuing Operations
-207.95M
Prev Year: -1.03B
YoY: +79.8%
Diluted NI Available to Com Stockholders
-207.95M
Prev Year: -1.03B
YoY: +79.8%
Basic EPS
-1.1
Prev Year: -5.59
YoY: +80.3%
Diluted EPS
-1.1
Prev Year: -5.59
YoY: +80.3%
Weighted Average Shares (basic)
188.69M
Prev Year: 184.20M
YoY: +2.4%
Weighted Average Shares (diluted)
188.69M
Prev Year: 184.20M
YoY: +2.4%
Total Operating Income as Reported
-206.30M
Prev Year: -1.05B
YoY: +80.3%
Total Expenses
3.45B
Prev Year: 2.94B
YoY: +17.3%
Net Income from Continuing and Discontinued Operation
-207.95M
Prev Year: -1.03B
YoY: +79.8%
Normalized Income
-235.26M
Prev Year: -214.13M
YoY: -9.9%
Interest Expense
34.75M
Prev Year: 31.97M
YoY: +8.7%
Interest Income
-
Net Interest Income
-39.36M
Prev Year: -37.27M
YoY: -5.6%
EBIT
-169.14M
Prev Year: -1.00B
YoY: +83.2%
EBITDA
52.44M
Prev Year: -789.33M
YoY: +106.6%
Reconciled Cost of Revenue
984.24M
Prev Year: 633.04M
YoY: +55.5%
Reconciled Depreciation
221.58M
Prev Year: 214.86M
YoY: +3.1%
Net Income from Continuing Operation Net Minority Interest
-207.95M
Prev Year: -1.03B
YoY: +79.8%
Values in USD

Exact Sciences key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$3.2B$2.8B$2.5B$2.1B$1.8B
Gross profit$2.3B$1.9B$1.8B$1.4B$1.3B
Operating income-$199.1M-$179.1M-$214.3M-$577.5M-$835.5M
Net income-$207.9M-$1.0B-$204.1M-$623.5M-$595.6M
Diluted EPS-$1.10-$5.59-$1.13-$3.54-$3.48
Total assets$5.9B$5.9B$6.5B$6.2B$6.7B
Total liabilities$3.5B$3.5B$3.3B$3.2B$3.3B
Shareholders' equity$2.4B$2.4B$3.1B$3.0B$3.4B
Cash and short-term investments$964.7M$1.0B$777.6M$632.1M$1.0B
Total debt$2.5B$2.8B$2.6B$2.4B$2.4B
Operating cash flow$491.4M$210.5M$156.1M-$223.6M-$102.2M
Capital spending$134.7M$136.0M$124.2M$214.5M$135.8M
Free cash flow$356.8M$74.5M$31.9M-$438.0M-$238.0M

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2014.

Questions and answers

What was Exact Sciences's revenue in fiscal year 2025?

$3.25 billion, up 17.7% from $2.76 billion in fiscal year 2024.

How much profit does Exact Sciences make?

Exact Sciences reported net income of -$207.95 million for fiscal year 2025 (6.4% of revenue); operating income was -$199.10 million.

How much cash and debt does Exact Sciences have?

At the end of fiscal year 2025: cash and short-term investments of $964.71 million and total debt of $2.52 billion.

What is Exact Sciences's free cash flow?

$356.78 million in fiscal year 2025 (operating cash flow of $491.44 million minus capital spending of $134.66 million).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube